ERS 2018: Severe eosinophilic asthma and the future of asthma care

ERS 2018: Severe eosinophilic asthma and the future of asthma care

Day two at the ERS 2018 congress has proved to be just as exciting as the first. Aside from our whole host of exciting booth activities, we ran our second and third respiratory leaders Q&A sessions with Professor Andrew Menzies-Gow and Professor Peter Barnes; exploring the changing management of severe eosinophilic asthma and the future of respiratory care.

In his session, Menzies-Gow discussed the radical change the severe eosinophilic asthma field has seen over the past decade. When he first began working in the therapy area, asthma was seen as one diagnosis, and healthcare professionals (HCPs) knew little about what was causing the disease on an individual basis. Ten years later, we can now endotype asthma so patients can be given the right treatment, at the right time, to significantly improve their quality of life.

But if patients present with more than one cause of disease, can they be given more than one biologic? While there are currently significant concerns regarding safety and cost, Menzies-Gow argued that with so many new, broader treatments on the horizon such as small molecules, HCPs may eventually be able to safely combine different therapies to provide a more personalised approach to care.

Whilst Prof. Menzies-Gow focussed on severe asthma, our second sessions with Prof. Barnes focused primarily on finding new ways to treat mild and moderate asthma. Thanks to the SYGMA trials, there is now strong evidence for using anti-inflammatory inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) combination inhalers as both maintenance and reliever therapy (MART). When used as reliever therapy, combination inhalers were shown to give patients greater control over their asthma, with a reduced exacerbation risk in comparison to short-acting beta agonists (SABAs).1,2 Barnes argued that anti-inflammatory MART can therefore provide a highly effective treatment regime for patients with the convenience of a single inhaler; representing the next stage in mild and moderate asthma management.

Discover more about severe eosinophilic asthma and the future of respiratory care here, and stay tuned for the final instalment of our respiratory leaders Q&A session.

For more information on ERS, please visit:

1. Bateman ED et al. N Engl J Med 2018; 378:1877–1887. 2. O’Byrne PM et al. N Engl J Med 2018; 378:1865–1876.

Similar topics

Related posts